Jose E Rodriguez-Borges
Overview
Explore the profile of Jose E Rodriguez-Borges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loureiro J, Seoane S, Sampaio-Dias I, Peluso-Iltis C, Guiberteau T, Brito B, et al.
J Med Chem
. 2024 Nov;
67(23):21505-21519.
PMID: 39610329
The incorporation of silicon bioisosteres into pharmacological structures has been used as a strategy to improve the therapeutic potential of drugs. However, no secosteroidal silicon-containing VDR ligands have been developed....
2.
Silva-Reis S, Costa V, da Silva D, Pereira D, Correia X, Garcia-Mera X, et al.
RSC Med Chem
. 2024 Sep;
PMID: 39290380
Neurodegenerative disorders comprise a series of heterogeneous conditions that affect millions of people worldwide, representing a significant health burden in both developed and developing countries. Without disease-modifying treatments currently available,...
3.
Silva-Reis S, Costa V, da Silva D, Pereira D, Correia X, Costa-Almeida H, et al.
Eur J Med Chem
. 2024 Feb;
267:116174.
PMID: 38306884
Neurodegenerative disorders of the central nervous system (CNS) such as Alzheimer's and Parkinson's diseases, afflict millions globally, posing a significant public health challenge. Despite extensive research, a critical hurdle in...
4.
Silva-Reis S, Correia X, Costa-Almeida H, Pires-Lima B, Maronde D, Costa V, et al.
ACS Med Chem Lett
. 2023 Dec;
14(12):1656-1663.
PMID: 38116429
This work describes the synthesis and pharmacological and toxicological evaluation of melanostatin (MIF-1) bioconjugates with amantadine (Am) via a peptide linkage. The data from the functional assays at human dopamine...
5.
Magalhaes C, Ducic T, Pereira R, Gonzalez-Berdullas P, Rodriguez-Borges J, Pereira D, et al.
Arch Biochem Biophys
. 2023 Jun;
743:109660.
PMID: 37263463
The mode of action toward gastric cancer cells of brominated Coelenteramine, an analogue of a metabolic product of a marine bioluminescent reaction, was investigated by synchrotron radiation-based Fourier Transform Infrared...
6.
Silva-Reis S, Sampaio-Dias I, Costa V, Correia X, Costa-Almeida H, Garcia-Mera X, et al.
ACS Chem Neurosci
. 2023 Feb;
14(4):554-572.
PMID: 36735764
Neurodegenerative diseases of the central nervous system (CNS) pose a serious health concern worldwide, with a particular incidence in developed countries as a result of life expectancy increase and the...
7.
Gonzalez-Berdullas P, Pereira R, Teixeira C, Silva J, Magalhaes C, Rodriguez-Borges J, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955406
Cancer is still a challenging disease to treat, both in terms of harmful side effects and therapeutic efficiency of the available treatments. Herein, to develop new therapeutic molecules, we have...
8.
Magalhaes C, Gonzalez-Berdullas P, Duarte D, Correia A, Rodriguez-Borges J, Vale N, et al.
Biomedicines
. 2021 Sep;
9(9).
PMID: 34572385
Photodynamic therapy (PDT) is an anticancer therapeutic modality with remarkable advantages over more conventional approaches. However, PDT is greatly limited by its dependence on external light sources. Given this, PDT...
9.
Sampaio-Dias I, Santejo M, Silva-Reis S, Liz M, Alcoholado C, Algarra M, et al.
ACS Chem Neurosci
. 2021 Sep;
12(19):3615-3624.
PMID: 34515466
Neurodegenerative disorders of the central nervous system are a class of heterogeneous pathologies affecting millions of people worldwide and represent a global health burden in developed and developing countries. Without...
10.
Sampaio-Dias I, Reis-Mendes A, Costa V, Garcia-Mera X, Brea J, Loza M, et al.
J Med Chem
. 2021 Apr;
64(9):6209-6220.
PMID: 33861612
The control of Parkinson's disease (PD) is challenged by the motor and non-motor fluctuations as well as dyskinesias associated with levodopa long-term therapy. As such, pharmacological alternatives to reduce the...